Rilzabrutinib, a reversible covalent Bruton's tyrosine kinase inhibitor: Absorption, metabolism, excretion, and absolute bioavailability in healthy participants

• Main Authors: Sibel Ucpinar (Author), Patrick F. Smith (Author), Li Long (Author), Fujun Li (Author), Hui Yan (Author), Jyoti Wadhwa (Author), Katherine A. Chu (Author), Jin Shu (Author), Philip Nunn (Author), Mengyao Li (Author)
• Format: Book
• Published: Wiley, 2023-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract This single‐center, open‐label, non‐randomized, two‐part, phase I study was conducted (1) to evaluate the absolute oral bioavailability of rilzabrutinib 400 mg tablet following an i.v. microtracer dose of ~100 μg [14C]‐rilzabrutinib (~1 μCi) and single oral dose of 400 mg rilzabrutinib tabl...